

Faculty of Medicine and Health Sciences: Research Development and Support 8 April 2019 (#11)

[Click on blue <u>hyperlink</u> for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit <a href="www.grants.nih.gov">www.grants.nih.gov</a> or <a href="www.grants.nih.

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Contact: RGMO Pre-Awards <a href="mailto:cdevries@sun.ac.za">cdevries@sun.ac.za</a>

### **Important Notices & News**

- New FOAs for NIH-MRC U.S.-South Africa Collaborative Research
- NIH recently released their annual <u>web reports</u> and <u>success rate data</u> with updated numbers for fiscal year (FY) 2018. NIH's budget increased \$2 billion over the previous year's appropriations. The average size of awards for Research Project Grants increased by 2.8 percent from \$520,429 to \$535,239 and the success rate went up as well from 18.7 percent in 2017 to 20.2 percent.
- Interested in the latest funding policies from your favorite NIH Institute or Center (IC)? Find funding strategies for each NIH-IC, in addition to NIH fiscal policies and budget overview, on the <u>NIH Funding</u> <u>Strategies page</u>
- A new <u>Behavioral and Social Sciences Research Template</u> is now available to guide investigators
  through the systematic development of a comprehensive clinical protocol. This template may be
  especially helpful to investigators who are less familiar with the information and the level of detail
  that is required in a clinical protocol.
- Findings of Research Misconduct (NOT-OD-19-094)
- Salary Limitation on AHRQ FY2019 Grants, Cooperative Agreements, and Contracts (NOT-HS-19-013)

#### 1. Targeted Prevention for Tickborne Diseases (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date Hyperlink: (RFA-Al-19-037)

**Application Due Date:** August 6, 2019 Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement**: The purpose of this Funding Opportunity Announcement (FOA) is to encourage the development of vaccines and other approaches for the prevention of Lyme disease and/or other tick-borne diseases.

**Budget**: NIAID intends to commit \$6 million in FY 2020 to fund 14 to 16 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

# 2. Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: CNS Data Generation (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: (RFA-DA-19-037)

Type: UM1

Type: R01

Application Due Date: May 8, 2019 and October 8, 2019Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** To support generation of single cell RNA-sequencing datasets for at least one brain region relevant to persistent HIV infection and opioid use disorder

**Budget**: NIDA intends to commit \$4M in FY19 and \$4M in FY20 to fund 1-2 applications for each receipt date. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

#### 3. Targeting Inflammasomes in Substance Abuse and HIV (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

Hyperlink: (RFA-DA-19-039)

Application Due Date: May 24, 2019 Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement**: The scientific objective of this Funding Opportunity Announcement is to encourage research to delineate the role of inflammasomes in the neuropathology produced by acute or chronic drug exposure and HIV infection. Understanding the involvement of inflammasomes in virus and drug-induced immune activation may help identify molecular markers and CNS immune cells associated with HIV-1 infection or disease progression among substance abuse populations, as well as identify novel therapies to target inflammasome activation or suppression to treat neuroinflammation and immune dysregulation aroused in these processes. **Budget**: NIDA intends to commit \$3,000,000.00 in FY 2019 to fund 6 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

#### 4. Revolutionizing Innovative, Visionary Environmental health Research (RIVER) (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: (RFA-ES-19-007)

Type: R35

Type: R01

Application Due Date: June 20, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NIEHS Revolutionizing Innovative, Visionary Environmental health Research (RIVER) program seeks to provide support for the majority of the independent research program for outstanding investigators in the Environmental Health Sciences, giving them intellectual and administrative freedom, as well as sustained support to pursue their research in novel directions in order to achieve greater impacts. The program seeks to identify individuals, regardless of career stage, with a potential for continued innovative and impactful research and combine their existing investigator-initiated research into a single award with a duration of up to 8 years and direct costs of \$600,000 and potentially up to \$750,000 based on current NIEHS funding to be consolidated into the award. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). If you are planning a basic experimental study with humans, you must apply to the companion RFA-ES-19-008 "Revolutionizing Innovative, Visionary Environmental health Research (RIVER) (R35 Basic Experimental Studies in Humans)".

**Budget:** NIEHS intends to commit \$4M in FY 2020 to fund 4-5 awards across this funding opportunity and its companion, RFA-ES-19-008. Allowable application budgets are related to the current NIEHS support which will be consolidated into the R35 award. Applicants may request up to \$600,000 in Direct Costs per year. If an individual has NIEHS funding beyond the \$600,000 DC level which will be consolidated given the guidelines above, they may add the additional funds plus 10% to a total of \$750,000 Direct Costs per year. The maximum project period is 8 years.

# 5. Revolutionizing Innovative, Visionary Environmental health Research (RIVER) (Basic Experimental Studies with Humans Required)

**Letter of Intent:** 30 days prior to the application due date

Hyperlink: (RFA-ES-19-008)

Type: R35

Application Due Date: June 20, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NIEHS Revolutionizing Innovative, Visionary Environmental health Research (RIVER) program seeks to provide support for the majority of the independent research program for outstanding investigators in the Environmental Health Sciences, giving them intellectual and administrative freedom, as well as sustained support to pursue their research in novel directions in order to achieve greater impacts. The program seeks to identify individuals, regardless of career stage, with a potential for continued innovative and impactful research and combine their existing investigator-initiated research into a single award with a duration of up to 8 years and direct costs of \$600,000 and potentially up to \$750,000 based on current NIEHS funding to be consolidated into the award. This funding opportunity is intended for basic experimental studies with humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants". These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that fit within this FOA include studies using human subjects to support a deeper understanding of the mechanisms underlying the effects of environmental exposures on human health, including molecular epidemiological studies. See the Comparison of Funding Opportunity Types by Clinical Trial Allowability table for additional guidance. Applicants not planning a basic experimental study with humans must apply to the companion RFA-ES-19-007 "Revolutionizing Innovative, Visionary Environmental health Research (RIVER) (R35 Clinical Trial Not Allowed)".

**Budget:** NIEHS intends to commit \$4M in FY 2020 to fund 4-5 awards across this funding opportunity and its companion, RFA-ES-19-007. Allowable application budgets are related to the current NIEHS support which will be consolidated into the R35 award. Applicants may request up to \$600,000 in Direct Costs per year. If an individual has NIEHS funding beyond the \$600,000 DC level which will be consolidated given the guidelines above, they may add the additional funds plus 10% to a total of \$750,000 Direct Costs per year. The maximum project period is 8 years.

### 6. Novel RNAs in Virology (including HIV) and Immune Regulation: Basic Science and Therapeutic Discovery (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: (PA-19-237)

Type: R21

**Application Due Date:** Standard dates & Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement**: The purpose of this Funding Opportunity Announcement (FOA) is to support basic science research, from early exploratory studies to therapeutic discovery and development, in novel biologically active viral and/or host RNAs involved in virology (including HIV biology) and immune regulation.

**Budget**: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

# 7. Limited Competition: Additional Sequencing for the Alzheimer's Disease Sequencing Project (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date Hyperlink: (PAR-19-234) Type: U01

Application Due Date: Standard dates Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement**: This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, and data calling that will support the generation of data for the Alzheimer's Disease Sequencing Project Follow-Up Study.

**Budget**: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period, with the maximum project period being five years.

Brief definitions of some NIH grant mechanisms: comprehensive list of extramural grant and cooperative agreement activity codes

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University

5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: \*Christa\* • Tel: 9838 • Email: \*cdevries@sun.ac.za\*\*